| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 26,963 | 42,290 | ||
| Short-term investments | 84,654 | 70,972 | ||
| Prepaid expenses and other current assets | 2,139 | 1,903 | ||
| Restricted cash, current portion | 90 | 20 | ||
| Total current assets | 113,846 | 115,185 | ||
| Property and equipment, net | 542 | 686 | ||
| Goodwill | 10,502 | 10,502 | ||
| Restricted cash, net of current portion | 210 | 210 | ||
| Total assets | 125,100 | 126,583 | ||
| Accounts payable | 474 | 2,366 | ||
| Accrued expenses and other current liabilities | 7,498 | 6,523 | ||
| Derivative liability, current | 0 | 370 | ||
| Total current liabilities | 7,972 | 9,259 | ||
| Royalty obligation | 2,000 | 2,000 | ||
| Deferred tax liability, net | 304 | 293 | ||
| Derivative liability, non-current | 23,160 | 10,260 | ||
| Other long-term liabilities | 117 | 197 | ||
| Total liabilities | 33,553 | 22,009 | ||
| Temporary equity, values issued-Series DPreferred Stock | 0 | 0 | ||
| Temporary equity, values issued-Series EPreferred Stock | 0 | 0 | ||
| Common stock0.001 par value 200,000,000 shares authorized at september30, 2025 and december31, 2024 17,827,635 and 10,471,934 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 18 | 11 | ||
| Additional paid-in capital | 526,290 | 508,774 | ||
| Accumulated other comprehensive income | 41 | -34 | ||
| Accumulated deficit | -434,802 | -404,177 | ||
| Temporary equity, values issued | - | 0 | ||
| Total stockholders equity | 91,547 | 104,574 | ||
| Total liabilities, mezzanine equity and stockholders equity | 125,100 | 126,583 | ||
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)